Editorial policy

mmjnow publishes US cannabis legal information and clinical summaries of medical conditions commonly qualifying under state programs. This page describes the editorial standards every page on the site is held to.

Source tier hierarchy

Every factual claim on mmjnow is sourced from one of the following tiers, preferring the highest available tier in each case:

Tier 1. Primary statute, regulator, or federal agency

• US state legislative sites (e.g. leg.state.fl.us, nysenate.gov).
• State medical-cannabis regulator pages (OMMU, GMCC, CRA, OCM, CRC, AMCC).
• US federal regulators: FDA prescribing information, DEA scheduling notices, US Department of Justice rulemaking.
• NIH agencies: National Cancer Institute, National Institute on Drug Abuse, National Institute of Mental Health, NCCIH, NIAMS, NHLBI, NIA, NIMH, NINDS.
• CDC for surveillance and clinical-practice context.

Tier 2. Scientific consensus and clinical guidelines

• National Academies of Sciences, Engineering, and Medicine (NASEM) consensus reports: primarily "The Health Effects of Cannabis and Cannabinoids" (2017) and its updates.
• VA / DoD Clinical Practice Guidelines.
• Specialty-society position statements (for example the American Academy of Ophthalmology on glaucoma, or the American Academy of Pediatrics on pediatric cannabis use).
• Peer-reviewed systematic reviews and meta-analyses in indexed journals.

Tier 3. Policy aggregators and cross-checks

• National Conference of State Legislatures (NCSL) cannabis overview.
• Marijuana Policy Project (MPP) state pages.
• NORML state law summaries.
• Ballotpedia for ballot-initiative history.
• Wikipedia for orientation and cross-reference; never as the sole source for a factual claim.

Medical-cannabis claim standards

For any claim about cannabis efficacy for a specific medical condition:

• Claims are tied to a published evidence tier from a Tier 1 or Tier 2 source. The NASEM 2017 evidence framework (conclusive / substantial / moderate / limited / insufficient) maps to four levels surfaced on the site: strong, moderate, limited, insufficient.
• Where FDA-approved products exist for an indication (for example Epidiolex for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex; dronabinol for AIDS-related anorexia and CINV), the FDA label is the authoritative source for that indication.
• Pages do not claim cannabis cures, treats, or prevents any disease where the primary evidence does not support that claim. Where evidence is insufficient, the page says so explicitly rather than implying uncertainty.
• Pediatric and pregnancy cautions are surfaced where the evidence base warrants them. Not hidden in disclaimers.

State-law standards

For any claim about a state's cannabis law:

• The primary statute citation is included in the state page's source list (for example Florida Statute §381.986, Texas Health and Safety Code Chapter 487, Michigan MCL 333.26421 et seq.).
• Possession limits, qualifying conditions, and registration mechanics are sourced from the state regulator's public page where one exists.
• Legislative-session bill statuses are cross-checked against the state legislature's bill tracker. Disposition is verified before any statement that a bill "passed," "failed," or "died in committee."

Independence

mmjnow is an independent information resource. The site is not a medical practice, not a law firm, and not a dispensary. It does not accept paid placements, sponsored content, affiliate referrals, or commission revenue from any cannabis operator, telemedicine clinic, or product brand. There are no advertisements and no third-party social embeds.

Corrections

For factual corrections, broken source links, or out-of-date statute citations, contact [email protected]. Corrections are reflected in the relevant page's last_updated field.

What this page is not

This page does not constitute medical or legal advice. See the disclaimer for the full posture on liability, scope, and reader responsibility.